Valye reports for unlimited access

Hyperion DeFi, Inc. is a publicly listed company on Nasdaq Capital Market (ticker: HYPD) focused on providing shareholders exposure to the Hyperliquid blockchain ecosystem. Hyperliquid is a decentralized Layer-1 blockchain designed for high-frequency, transparent trading with rapid block times. The company generates revenue primarily through native staking of its HYPE tokens and commission income from blockchain validation services, operating a co-branded validator node with third-party operators. It also offers proprietary HYPE Asset Use Service agreements, temporarily leasing HYPE tokens for usage-based fees. The company has wound down its prior ophthalmic technology operations and focuses on digital asset-related activities. Financially, it holds significant digital assets and intangible assets related to its blockchain activities, maintains strong liquidity, and has reported positive net income in recent periods. The company has engaged in capital raising activities and strategic partnerships to support its operations and growth.

Royalty Management Holding Corporation (RMHC) was initially formed as a blank check company in 2021 to pursue a business combination. In October 2023, RMHC merged with Royalty Management Corporation, becoming a royalty company focused on acquiring and structuring cash flow streams from assets primarily in natural resources and infrastructure sectors. The company’s investments include intellectual property, real estate, permits, and natural resource properties, as well as service businesses supporting infrastructure expansion. RMHC changed its incorporation from Delaware to Florida in 2025. The company’s revenue growth in 2025 was driven by increased volume and a new contract in its environmental services subsidiary. Financially, RMHC maintains positive working capital and liquidity ratios as of mid-2026, with a focus on funding corporate and public company costs.

Autonomix Medical, Inc. develops a catheter-based medical device platform designed to sense neural signals and deliver targeted radiofrequency ablation for treatment of nervous system disorders. The technology integrates a proprietary microchip-enabled sensing architecture to detect low-amplitude neural signals within the vascular system, aiming to improve precision and consistency of nerve-targeted therapies. The company is initially focused on treating pain associated with pancreatic cancer, conducting early clinical proof-of-concept and expansion studies. The platform's potential applications include other visceral pain conditions, hypertension, cardiovascular disease, and nerve-related disorders, pending further development and clinical validation. Autonomix has secured multiple U.S. patents protecting its neuromodulation and treatment technologies. The company is in the development stage with no reported revenues and is funding operations through equity and warrant exercises. As of June 30, 2026, it reported cash and cash equivalents of $3.46 million and a net loss of $2.73 million for the quarter. Management includes experienced executives in medical device development and clinical research. The company is listed on Nasdaq and recently regained compliance with listing rules following a reverse stock split.

STEM INC operates in the renewable energy technology sector, providing AI-enabled software, edge computing, and services primarily related to energy storage systems and distributed generation. The company historically generated most revenue from battery resales but shifted focus in 2024 to software and services, involving significant operational changes. STEM INC's offerings include hardware energy storage systems combined with long-term software service agreements via its PowerTrack Optimizer platform. The company faces a lengthy sales and installation cycle, supply chain risks due to reliance on limited suppliers, and customer concentration risks. STEM INC competes with traditional utilities and other energy storage providers, with competition intensified by AI-enabled offerings. The company is subject to regulatory, cybersecurity, and market acceptance risks. Financially, STEM INC has incurred significant losses and continues to invest in scaling its software and services business.

JATT II Acquisition Corp. is a Cayman Islands exempted company operating as a special purpose acquisition company (SPAC). It completed its IPO in April 2026, raising $60 million, and a concurrent private placement raised an additional $3 million. The proceeds were placed in a trust account for public shareholders. In June 2026, JATT entered into a Business Combination Agreement to merge with Talawar Tx Inc., with JATT surviving as a wholly-owned subsidiary. The combined entity will operate through Talawar Tx Inc. The transaction includes a PIPE financing of $225 million. The company has adopted customary governance and incentive plans to support the combined business.

Alaska Silver Corp. is a mining exploration company focused on silver and associated metals, primarily operating in Alaska. The company is engaged in exploration and resource development activities at its Illinois Creek project and other sites, with recent efforts including drilling programs and technical report updates. It has undertaken capital raising through public offerings to support its exploration and development initiatives. The company maintains liquidity slightly above its current liabilities as of mid-2026 and reports ongoing net losses consistent with exploration-stage mining companies.

CSLM Digital Asset Acquisition Corp III, Ltd is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in 2024. Its primary objective is to identify and complete a business combination with one or more companies operating in sectors related to digital assets, Web3 technologies, financial services infrastructure, and blockchain-driven business models, with a focus on emerging and frontier markets. The company completed its initial public offering in August 2025, raising $230 million, and simultaneously conducted a private placement. The proceeds are held in a trust account pending the completion of a business combination. The company announced a non-binding letter of intent in December 2025 with First Digital Group Ltd. for a potential business combination to create a global stablecoin and digital payments leader. The company has not yet commenced operations and generates income primarily from interest on its cash holdings. It plans to consummate its initial business combination within 24 months of the IPO, subject to shareholder approval or tender offer mechanisms. The management team leverages extensive experience and networks in frontier growth markets and emphasizes ESG principles in its investment approach [S1][N1].

Bitcoin Infrastructure Acquisition Corp Ltd is a publicly reporting entity with limited publicly available information on its business operations, sector, or industry classification. The company files regular SEC reports, including a recent 10-K and 10-Q, which provide financial snapshots but do not elaborate on its business model or strategic focus.

IIOT-OXYS, Inc. is an early-stage technology company specializing in edge computing solutions for the Industrial Internet of Things. The company develops hardware, software, and AI algorithms to monitor and predict conditions in various industrial and environmental applications. Their approach emphasizes local data processing at the edge, complemented by cloud-based AI, aiming to improve asset reliability, operational efficiency, and risk minimization. The company serves markets including smart manufacturing and smart infrastructure, focusing on predictive maintenance and operational insights. IIOT-OXYS competes with large cloud-centric firms and startups in edge computing, differentiating through its edge-first strategy and use of open-source tools combined with proprietary content. The company has limited staff and relies on contractors, with funding constraints impacting growth. Financially, as of mid-2026, the company reported no revenue and a net loss, with liquidity ratios indicating significant current liabilities relative to assets.

KRAKacquisition Corp operates as a special purpose acquisition company (SPAC) with no current operations other than holding cash from its IPO proceeds. Its business purpose is to identify and complete a Business Combination with a target company, preferably in the digital asset ecosystem, including infrastructure and services that connect decentralized finance and traditional finance. The company benefits from the expertise and network of its Sponsor partners, including Kraken, a leading crypto platform, and venture capital firms. The company’s financial position as of mid-2026 shows strong liquidity and nominal liabilities, consistent with its status as a shell company preparing for a Business Combination.

StubHub Holdings, Inc. is a global marketplace operator specializing in secondary ticketing for live events, including sports, concerts, and theater. The company operates primarily through two brands: StubHub and viagogo. Its platform integrates technology for comprehensive event ticketing, global distribution networks, data analytics to optimize transactions, and strong brand recognition to attract millions of buyers and sellers. StubHub is pursuing growth by expanding into original issuance ticketing, enabling content rights holders to list tickets directly on its marketplace. The business is subject to significant seasonality and variability tied to event schedules and consumer demand. StubHub faces competition from various ticketing platforms and must navigate complex regulatory environments across multiple jurisdictions. The company is controlled by its founder and CEO and has disclosed material weaknesses in financial reporting controls. Financially, as of mid-2026, StubHub maintains a liquidity position with over $1.6 billion in cash and near parity between current assets and liabilities.

Liftoff Mobile, Inc. is a company with recent SEC quarterly financial disclosures indicating ongoing operations and liquidity management. The company reported a net loss in the latest quarter and maintains a current ratio above 1, suggesting sufficient short-term asset coverage of liabilities. Publicly available information includes a recent earnings call summary but lacks detailed disclosure on the company's sector, industry, or specific business model.

Karyopharm Therapeutics Inc. develops and commercializes first-in-class small molecule inhibitors of exportin 1 (XPO1), a nuclear export protein, for cancer treatment. Its lead product, XPOVIO® (selinexor), is approved in the U.S. for multiple myeloma and diffuse large B-cell lymphoma and is marketed domestically and internationally. The company is conducting late-stage clinical trials for selinexor in myelofibrosis and endometrial cancer, aiming to expand its therapeutic indications. Commercial operations include a dedicated U.S. sales force and patient support programs, with international commercialization managed by partners. The company has completed significant financing transactions to provide working capital and has a substantial accumulated deficit and ongoing net losses. It faces liquidity challenges and is evaluating strategic alternatives to sustain operations.

Indaptus Therapeutics, Inc. operates as a clinical-stage biotechnology company developing a patented systemically-administered immunotherapy platform targeting cancer and viral diseases. Its product candidates remain in preclinical or early clinical stages, with no approved or commercialized products. The company has recently discontinued enrollment in its Combination Study and currently has no active clinical trials. It has conducted a Phase 1 study evaluating Decoy20 combined with Tislelizumab, enrolling over 20 patients and achieving clinical milestones. Indaptus holds patents in multiple countries for its Decoy platform and has expanded clinical trials to Canada. The company has raised capital through convertible promissory notes and securities deals, but faces significant financial challenges, including recurring losses and liquidity concerns. Management and board changes have occurred recently, and the company is evaluating strategic alternatives for its development programs and business operations.

Cabaletta Bio, Inc. focuses on developing engineered T cell therapies for autoimmune diseases using its proprietary CABA® platform, specifically the CARTA approach. The lead product candidate, rese-cel, is a fully human CD19-CAR T cell therapy designed to achieve deep and durable B cell depletion with a single infusion, aiming to reset the immune system and provide meaningful clinical responses without chronic therapy. The company is conducting multiple Phase 1/2 and registrational clinical trials across a range of autoimmune diseases including dermatomyositis, systemic lupus erythematosus, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris. Cabaletta has received several FDA designations such as Fast Track, Orphan Drug, Rare Pediatric Disease, and RMAT to support development. The company has a strong management team with expertise in cell therapy development and commercialization. Financially, as of June 30, 2026, Cabaletta holds over $225 million in cash and equivalents, maintains strong liquidity ratios, and reported a net loss of $51 million for the quarter ending that date.

Falcon's Beyond Global, Inc. operates in the experiential entertainment and attractions industry, providing services including master planning, attraction design, content production, and software. The company generates revenue from both service contracts and product sales, with significant recent growth in new attractions contracts. It holds equity method investments in joint ventures such as PDP and Karnival, which impact its financial results. The company has experienced fluctuations in net income and expenses related to business expansion and acquisitions.

FitLife Brands, Inc. is a publicly traded company listed on the Nasdaq Capital Market under the ticker FTLF. The company is incorporated in Nevada and headquartered in Omaha, Nebraska. Its leadership team includes experienced executives and a board of directors with expertise in finance, marketing, and consumer products. The company reported net income and earnings per share for the quarter ended June 30, 2026, and maintains liquidity with a current ratio above 1.4. The board actively oversees risk management through regular meetings and updates with management.

Grace Therapeutics, Inc. develops and commercializes novel drug formulations targeting rare and orphan diseases. Its lead product candidate, GTx-104, is an injectable formulation of nimodipine designed for intravenous infusion in patients with aneurysmal subarachnoid hemorrhage (aSAH), aiming to improve upon the limitations of oral nimodipine. The company’s pipeline also included GTx-102 and GTx-101 targeting ataxia-telangiectasia and postherpetic neuralgia, respectively, but internal development funding for these was discontinued in June 2026. Grace leverages the FDA’s 505(b)(2) regulatory pathway and has orphan drug designation for its candidates. The company completed a pivotal Phase 3 STRIVE-ON trial for GTx-104, which met its primary endpoint and demonstrated clinical and pharmacoeconomic benefits. The NDA for GTx-104 was accepted by the FDA but received a CRL in April 2026 citing manufacturing and non-clinical data issues. The company is focused on addressing these issues and resubmitting the NDA. Grace reported a net loss of $15.79 million for the quarter ended June 30, 2026, with strong liquidity and recently completed a $10 million private placement to support ongoing operations and regulatory activities.

Advanced Flower Capital Inc. is a publicly traded investment company that operates under the regulatory framework of a regulated investment company (RIC). It is subject to U.S. federal income tax rules that require it to distribute a significant portion of its taxable income to shareholders to maintain favorable tax status. The company’s portfolio includes investments that may generate income before cash receipt, such as original issue discount and payment-in-kind interest. It manages liquidity and distribution obligations within the constraints of asset coverage ratios and financial covenants. The company’s common stock price is subject to volatility driven by operational performance, market conditions, and regulatory developments. Recent SEC filings and earnings call disclosures provide detailed insights into its financial position and business operations.

Abeona Therapeutics Inc. develops and commercializes cell and gene therapies targeting rare and life-threatening diseases. Its lead product, ZEVASKYN®, is an autologous cell-based gene therapy approved by the FDA for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic skin disorder. The company manufactures ZEVASKYN® at its Cleveland, Ohio cGMP facility and distributes it through a network of qualified treatment centers. Abeona’s pipeline includes AAV-based gene therapies for ophthalmic diseases using novel AIM™ capsids. The company focuses on expanding its commercial infrastructure, including treatment centers and insurance coverage, while addressing manufacturing complexities inherent to autologous cell therapies.

Cocrystal Pharma, Inc. operates as a single business entity focused on discovering and developing small molecule antiviral therapeutics for serious viral diseases caused by RNA viruses. The company employs a proprietary platform combining computational chemistry, medicinal chemistry, and X-ray crystallography to design inhibitors targeting conserved viral replication enzymes. Their pipeline includes CC-42344 for influenza A and CDI-988 for norovirus and coronaviruses. The company has conducted clinical trials including Phase 1 and Phase 2a studies, with recent FDA Fast Track designation for CDI-988. Financially, the company reported modest government contract revenue and a net loss in the latest quarter, maintaining liquidity with cash and equivalents and a current ratio above 1 [S1][S2].

Pelthos Therapeutics Inc. is a bio-pharmaceutical company dedicated to commercializing innovative therapeutic products addressing unmet medical needs in dermatology. Formed in July 2025 through a merger, the company’s portfolio includes three FDA-approved products: ZELSUVMI for molluscum contagiosum, XEPI for impetigo, and XEGLYZE for head lice. ZELSUVMI, launched shortly after the merger, is the first topical nitric oxide releasing agent approved for molluscum contagiosum, a viral skin infection affecting millions in the U.S. XEPI and XEGLYZE were acquired in late 2025, with commercial relaunch and launch activities underway. The company holds exclusive licenses to proprietary technology platforms and manufacturing capabilities. Pelthos has secured financing through a $50 million senior secured term loan and PIPE financing to support commercialization and working capital. Recent financial disclosures indicate ongoing net losses and a material weakness in internal controls related to convertible debt accounting, with remediation efforts in progress. The company’s commercial strategy focuses on expanding product availability and market penetration in dermatology [S1][S2].

Avai Bio, Inc. (formerly Avant Technologies Inc.) operates in the AI technology and IT consulting sector, focusing on developing advanced AI solutions using proprietary unsupervised and supervised learning methods. The company has acquired key AI assets including Avant! AI and digital technology portfolios to enhance its offerings. Despite these acquisitions, the company has a limited operating history and has not achieved profitability. It faces challenges related to liquidity, capital requirements, and market acceptance of its products. The company trades on the OTC QB market under the ticker AVAI.

Spire Global, Inc. is a space-based data and analytics company founded in 2012, headquartered in Vienna, Virginia, with subsidiaries across several countries. It operates a proprietary constellation of LEMUR nanosatellites and a global ground station network to collect radio frequency data from Earth. The company offers four main data products: clean data, smart data enhanced with third-party inputs, predictive data using AI and machine learning, and data solutions providing actionable recommendations. Its solutions serve industries such as agriculture, logistics, financial services, insurance, aviation, energy, and academia. Key verticals include space reconnaissance for defense and security, aviation tracking using ADS-B signals, weather and climate analytics using radio occultation and GNSS reflectometry, and space services enabling customers to deploy their own satellite constellations. Spire sold its maritime business in 2025 but retains certain government-related maritime operations. The company emphasizes direct sales with a land-and-expand model and invests heavily in R&D to maintain competitive advantage. It faces competition from specialized firms in each vertical but believes its integrated platform and data quality provide differentiation [S1].

McGraw Hill, Inc. is a leading global education company with over 137 years of history, providing proprietary content, software, and data-driven learning solutions across K-12, higher education, and professional markets. The company leverages artificial intelligence and extensive data analytics to deliver personalized learning experiences at scale. Its business model includes blended digital and print offerings sold primarily through multi-year contracts to educational institutions and direct-to-student channels. Key digital platforms include ConnectEd, ALEKS, and McGraw Hill Plus, supporting millions of learners. The company pursues organic growth through product innovation and inorganic growth via acquisitions and partnerships. McGraw Hill operates globally, with significant presence in the U.S. and over 100 countries internationally.

Zenas BioPharma is a clinical-stage global biopharmaceutical company specializing in immunology and inflammation (I&I) therapies targeting autoimmune diseases. The company’s core strategy involves acquiring and developing product candidates with potential clinical benefits for autoimmune conditions. Its lead product candidate, obexelimab, is designed to inhibit B cell activity by co-engaging CD19 and FcγRIIb receptors, aiming to provide a differentiated mechanism that inhibits rather than depletes B cells. Obexelimab is in late-stage development for IgG4-related disease, relapsing multiple sclerosis, and systemic lupus erythematosus. The company also develops orelabrutinib, a CNS-penetrant BTK inhibitor for progressive multiple sclerosis, and early-stage oral inhibitors ZB021 and ZB022 targeting IL-17 and TYK2 pathways respectively. Zenas BioPharma has partnered regional rights for certain programs and maintains a leadership team with extensive biopharmaceutical experience. The company has no approved products or commercial revenue to date.

BK Technologies Corporation is a holding company with an operating subsidiary that designs, manufactures, and markets public safety grade communications products and services. The company’s Radio product group offers two-way land mobile radios (LMRs) that are P25 compliant, serving government and public safety customers including emergency responders, homeland security, and military agencies. The Solutions product group provides smartphone applications such as InteropONE, a Push-to-talk-Over-Cellular SaaS service enabling interoperability across carriers, and LocateONE, a real-time personnel and asset tracking solution integrated with GIS mapping. BK Technologies focuses primarily on the government and public safety market, with sales conducted directly or through dealers and SaaS resellers. The company employs a hybrid manufacturing strategy combining internal and contract manufacturing. Engineering efforts focus on next-generation P25 digital radios, with significant R&D investment. Financially, as of mid-2026, the company maintains strong liquidity and reported net income and earnings per share for the quarter ending June 30, 2026.

Venu Holding Corp is a company focused on live entertainment, with substantial projects valued at $1.1 billion underway and collaborations with established partners. The company has publicly disclosed financial results showing net losses and liquidity challenges. It has engaged in related-party transactions and additional debt financing. Recent business developments include a terminated public offering and strategic partnerships.

Charlotte's Web Holdings, Inc. is a benefit company incorporated in British Columbia and headquartered in Louisville, Colorado. It is a market leader in the United States for hemp-derived cannabidiol (CBD) and botanical-based wellness products, including functional mushroom gummies. The company operates a cGMP-compliant production facility and grows proprietary hemp through contract farming in multiple U.S. states and Canada. Its product portfolio includes hemp oil tinctures, gummies, capsules, topicals, and pet products. Charlotte's Web also pursues research and development through its CW Labs division and has formed a joint venture to develop FDA-approved botanical drugs. The company is publicly traded on the Toronto Stock Exchange and OTCQB in the U.S.

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing innovative therapeutic products addressing unmet medical needs in dermatology. Formed in July 2025 through a merger, the company’s commercial portfolio includes three FDA-approved products: ZELSUVMI, a topical nitric oxide releasing agent for molluscum contagiosum; XEPI, a non-fluorinated quinolone cream for impetigo; and XEGLYZE, a topical treatment for head lice. The company’s proprietary NITRICIL technology platform enables stable and targeted nitric oxide delivery. Pelthos has secured financing through a $50 million senior secured term loan and PIPE financing to support commercialization and working capital. The company reported net losses in recent quarters but has generated revenue from its commercial products. It is addressing a material weakness in internal controls related to convertible debt accounting. Multiple analyst firms have initiated coverage with buy or overweight recommendations.

SBC Medical Group Holdings Inc operates primarily in the medical aesthetic services sector, managing and operating cosmetic surgery clinics and related medical services. The company has a governance structure with a five-member board, including three independent directors, and executive leadership with expertise in medical practice, corporate development, and finance. SBC Medical Group is publicly traded on Nasdaq under the ticker SBC since 2024. The company maintains strong liquidity and reported positive net income in the most recent quarter. It actively manages risk through board oversight and committee functions. Recent strategic actions include focusing on core operations by divesting subsidiaries and forming strategic alliances to enhance service offerings.

Cellectar Biosciences, Inc. operates as a clinical-stage biopharmaceutical company specializing in oncology drug development. Its lead product candidate, iopofosine I 131, is being developed for treatment of Waldenstrom Macroglobulinemia and pediatric high-grade glioma. The company is engaged in clinical trials including Phase 1 and Phase 2 studies, with recent positive data reported. Cellectar is preparing regulatory submissions to the FDA for accelerated approval and is in dialogue with the EMA for conditional marketing approval. The company has strengthened its financial position through recent financing activities and maintains a strong liquidity profile as of mid-2026. The leadership team and board have extensive experience in biotechnology and finance sectors [S1][S2][N1][N2].

Aveanna Healthcare Holdings, Inc. operates in the healthcare services sector, providing specialized home healthcare and related services. The company has publicly reported financial results through SEC filings, including a 10-K annual report and a 10-Q quarterly report. Its business model includes organic growth and acquisitions, such as the recent acquisition of Family First Holding. The company focuses on operational execution and growth in specialty and home health services.

Aebi Schmidt Holding AG specializes in manufacturing and upfitting specialty vehicles and equipment for snow removal, municipal maintenance, commercial trucking, goods transport, and agriculture. The company operates globally with a strong presence in North America and Europe, supported by a portfolio of established brands with long histories. Its product offerings include snowplows, sweepers, truck bodies, chassis, and electric vehicles for last-mile delivery. The company emphasizes innovation through research and development and maintains a broad supplier network to support production. Seasonality impacts sales, with higher activity in the winter months due to public procurement cycles. The company completed a significant acquisition of The Shyft Group in 2025, enhancing its North American market position and product range [S1].

Rockwell Medical, Inc. develops, manufactures, commercializes, and distributes hemodialysis products, focusing on liquid and dry acid and bicarbonate concentrates used in dialysis treatments for patients with end-stage kidney disease (ESKD). The company operates manufacturing facilities in Michigan, Texas, and Iowa, and delivers products primarily to dialysis clinics in the United States and internationally. Rockwell Medical is regulated by the FDA and maintains ISO 13485 certification, adhering to current Good Manufacturing Practices and industry standards. The company has a commercial organization focused on expanding revenue within its current customer base and acquiring new accounts to increase market share in the hemodialysis concentrates sector. Rockwell Medical operates in a single reportable segment: the hemodialysis market. A significant customer is DaVita, Inc., which accounted for 16% of net product sales in 2025. The company has experienced a decline in revenue from $101.5 million in 2024 to $69.3 million in 2025, with a net loss of $5.3 million in 2025. The company faces competition from larger firms with broader renal product portfolios and is subject to risks including pricing pressures, raw material cost increases, and changes in treatment modalities that may reduce demand for its products.

Hepion Pharmaceuticals, Inc. is a publicly traded company with recent SEC filings including a 10-K annual report and a 10-Q quarterly report providing financial and operational data. The company reported a net loss and negative earnings per share for the quarter ended June 30, 2026. It maintains strong liquidity ratios as of that date. Corporate actions in recent years include leadership changes, a reverse stock split, a transition to OTC Markets following Nasdaq delisting notice, and partnerships to commercialize diagnostic tests. The company has disclosed no material changes to its risk factors since its 2025 annual report.